BioDelivery Sciences International (NASDAQ:BDSI) Sees Unusually-High Trading Volume

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares saw an uptick in trading volume on Friday . 11,230,170 shares changed hands during trading, an increase of 1,043% from the previous session’s volume of 982,129 shares.The stock last traded at $4.65 and had previously closed at $4.40.

A number of research analysts have issued reports on the company. BidaskClub raised BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 11th. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a report on Tuesday, May 21st. Finally, Cantor Fitzgerald set a $8.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $6.20.

The stock’s fifty day moving average is $4.46. The company has a debt-to-equity ratio of 1.90, a current ratio of 2.88 and a quick ratio of 2.57.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. The company had revenue of $19.77 million during the quarter, compared to the consensus estimate of $19.60 million. On average, research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.14 EPS for the current fiscal year.

In other news, Director Mark A. Sirgo sold 90,706 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $4.39, for a total transaction of $398,199.34. Following the completion of the transaction, the director now directly owns 2,031,714 shares of the company’s stock, valued at approximately $8,919,224.46. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $5.19, for a total value of $41,520.00. Following the transaction, the director now directly owns 606,254 shares of the company’s stock, valued at $3,146,458.26. The disclosure for this sale can be found here. Insiders sold 4,429,743 shares of company stock valued at $21,711,638 over the last three months. 8.94% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. Advisor Group Inc. raised its stake in shares of BioDelivery Sciences International by 56.3% during the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock worth $40,000 after buying an additional 3,943 shares during the period. First Allied Advisory Services Inc. acquired a new position in shares of BioDelivery Sciences International during the 1st quarter worth approximately $58,000. Means Investment CO. Inc. acquired a new position in shares of BioDelivery Sciences International during the 1st quarter worth approximately $59,000. QCM Cayman Ltd. acquired a new position in shares of BioDelivery Sciences International during the 1st quarter worth approximately $35,000. Finally, Close Asset Management Ltd raised its stake in shares of BioDelivery Sciences International by 1,340.0% during the 1st quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock worth $95,000 after buying an additional 16,750 shares during the period. 56.73% of the stock is owned by institutional investors and hedge funds.

BioDelivery Sciences International Company Profile (NASDAQ:BDSI)

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: Trade Deficit

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.